Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00240214 |
Date of registration:
|
13/10/2005 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Study Evaluating Rapamune in Patients After Kidney Transplantation
|
Scientific title:
|
An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime |
Date of first enrolment:
|
April 2001 |
Target sample size:
|
500 |
Recruitment status: |
Terminated |
URL:
|
http://clinicaltrials.gov/show/NCT00240214 |
Study type:
|
Observational |
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Germany
| | | | | | | |
Contacts
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Germany, medinfoDEU@wyeth.com |
|
Name:
|
Medical Monitor |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Wyeth is now a wholly owned subsidiary of Pfizer |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients having received a renal allograft from a cadaveric or living donor with low
or moderate risk of developing acute rejection episodes.
Exclusion Criteria:
- Contraindications according to Summary of the Product Characteristics (SmPC).
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Renal Transplantation
|
Intervention(s)
|
Drug: sirolimus
|
Secondary ID(s)
|
0468E-100875
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|